belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.
Company profile
Ticker
BLTE
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BLTE stock data
Latest filings (excl ownership)
6-K
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22 Mar 24
6-K
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
11 Mar 24
20-F
2023 FY
Annual report (foreign)
11 Mar 24
6-K
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
6-K
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
13 Nov 23
6-K
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
6 Nov 23
S-8
Registration of securities for employees
19 Sep 23
6-K
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
9 Aug 23
6-K
Belite Bio Completes Enrollment in Pivotal Global Phase 3
24 Jul 23
6-K
Current report (foreign)
16 Jun 23
Latest ownership filings
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
SC 13G
Lin Yu-Hsin
12 Feb 24
SC 13G
Lin Bioscience International Ltd.
12 Feb 24
144
Notice of proposed sale of securities
28 Dec 23
144
Notice of proposed sale of securities
28 Dec 23
144
Notice of proposed sale of securities
28 Nov 23
144
Notice of proposed sale of securities
16 Nov 23
144
Notice of proposed sale of securities
16 Nov 23
144
Notice of proposed sale of securities
31 Aug 23
Financial summary
Quarter (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Institutional ownership, Q2 2023
59.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 14.87 bn |
Total shares | 17.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lin Bioscience International | 16.43 mm | $0.00 |
Atria Wealth Solutions | 814.50 k | $11.64 bn |
Armistice Capital | 210.92 k | $3.01 bn |
STT State Street | 13.39 k | $188.86 mm |
BLK Blackrock | 966.00 | $13.80 mm |
MS Morgan Stanley | 438.00 | $6.26 mm |
UBS UBS Group AG - Registered Shares | 300.00 | $4.29 mm |
Proequities | 0.00 | $0.00 |
News
HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target
22 Mar 24
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22 Mar 24
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
13 Mar 24
Belite Bio Q4 EPS $(0.25) Beats $(0.30) Estimate
12 Mar 24
Press releases
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22 Mar 24
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
11 Mar 24
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
4 Mar 24